Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

被引:1
|
作者
Kato, Junji [1 ]
Namikawa, Kenjiro [2 ]
Uehara, Jiro [3 ]
Nomura, Motoo [4 ]
Nakamura, Yasuhiro [5 ]
Uhara, Hisashi [1 ]
Uchi, Hiroshi [6 ]
Yoshikawa, Shusuke [7 ]
Kiniwa, Yukiko [8 ]
Nakamura, Yoshiyuki [9 ]
Miyagawa, Takuya [10 ]
Matsushita, Shigeto [11 ]
Takenouchi, Tatsuya [12 ]
Hatta, Naohito [13 ]
Ohno, Fumitaka [14 ]
Maeda, Taku [15 ,16 ]
Fukushima, Satoshi [17 ]
Yamazaki, Naoya
机构
[1] Sapporo Med Univ, Dept Dermatol, Sapporo, Hokkaido, Japan
[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Dermatol Oncol, Tokyo, Japan
[4] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan
[5] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Dept Dermatooncol, Fukuoka, Japan
[7] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan
[8] Shinshu Univ, Dept Dermatol, Nagano, Japan
[9] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan
[10] Univ Tokyo, Dept Dermatol, Grad Sch Med, Tokyo, Japan
[11] Natl Hosp Org Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan
[12] Niigata Canc Ctr, Dept Dermatol, Niigata, Japan
[13] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan
[14] Kyushu Univ, Dept Dermatol, Fukuoka, Japan
[15] Hokkaido Univ, Dept Plast & Reconstruct Surg, Fac Med, Sapporo, Hokkaido, Japan
[16] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[17] Kumamoto Univ, Dept Dermatol & Plast Surg, Kumamoto, Japan
关键词
DISCONTINUATION;
D O I
10.1111/bjd.21276
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:594 / 596
页数:3
相关论文
共 50 条
  • [31] Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study
    Yang, Xiaolin
    Yin, Xianli
    Qu, Xiaozhou
    Guo, Geyang
    Zeng, Yidong
    Liu, Wu
    Jagielski, Mateusz
    Liu, Zhenyang
    Zhou, Huijun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023,
  • [32] Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
    Valentin, Julie
    Ferte, Thomas
    Dorizy-Vuong, Valerie
    Dousset, Lea
    Prey, Sorilla
    Dutriaux, Caroline
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Gerard, Emilie
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [33] Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy
    Sandhu, Shahneen
    Atkinson, Victoria
    Cao, Maria Gonzalez
    Medina, Theresa
    Rivas, Ainara Soria
    Menzies, Alexander M.
    Caro, Ivor
    Roberts, Louise
    Song, Yuyao
    Yan, Yibing
    Guo, Yu
    Xue, Cloris
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 180 - 190
  • [34] Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study
    Yang, Qinzhu
    Huang, Haofan
    Zhang, Guizhi
    Weng, Nuoqing
    Ou, Zhenkai
    Sun, Meili
    Luo, Huixing
    Zhou, Xuhui
    Gao, Yi
    Wu, Xiaobin
    THORACIC CANCER, 2023, 14 (33) : 3266 - 3274
  • [35] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Wang, Yunchao
    Yang, Xiaobo
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Nan
    Yang, Xu
    Cong, Ning
    Zhang, Junwei
    Zhu, Chengpei
    Zhang, Longhao
    Hou, Xiaorong
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2197 - 2204
  • [36] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Yunchao Wang
    Xiaobo Yang
    Yanyu Wang
    Jingnan Xue
    Nan Zhang
    Xu Yang
    Ning Cong
    Junwei Zhang
    Chengpei Zhu
    Longhao Zhang
    Xiaorong Hou
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2197 - 2204
  • [37] Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study
    Matsuya, Taisuke
    Nakamura, Yasuhiro
    Matsushita, Shigeto
    Tanaka, Ryota
    Teramoto, Yukiko
    Asami, Yuri
    Uehara, Jiro
    Aoki, Megumi
    Yamamura, Kentaro
    Nakamura, Yoshiyuki
    Fujisawa, Yasuhiro
    Livingstone, Elisabeth
    Zimmer, Lisa
    Schadendorf, Dirk
    Kagamu, Hiroshi
    Fujimoto, Manabu
    Honma, Masaru
    Ishida-Yamamoto, Akemi
    Araki, Ryuichiro
    Yamamoto, Akifumi
    JOURNAL OF DERMATOLOGY, 2020, 47 (06): : 629 - 635
  • [38] Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature
    Zumelzu, Coralie
    Alexandre, Marina
    Le Roux, Christelle
    Weber, Patricia
    Guyot, Alexis
    Levy, Annie
    Aucouturier, Francoise
    Mignot-Grootenboer, Sabine
    Caux, Frederic
    Maubec, Eve
    Prost-Squarcioni, Catherine
    FRONTIERS IN MEDICINE, 2018, 5
  • [39] Concurrent Radiation Therapy for Patients with Metastatic Melanoma and Receiving Anti-Programmed-Death 1 Therapy: A Retrospective Monocentric Study on 141 Patients
    Atallah, V.
    Amestoy, F.
    Gerard, E.
    Leduc, N.
    Huchet, A.
    Beylot-Barry, M.
    Dupin, C.
    Prey, S.
    Dousset, L.
    Trouette, R.
    Ouabrache, N.
    Maillot, O.
    Martin, M.
    Gillon, P.
    Dutriaux, C.
    Vendrely, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S78 - S78
  • [40] High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study
    Zhao, Lingdi
    Li, Tiepeng
    Song, Yongping
    Yang, Yonghao
    Ma, Baozhen
    Zhang, Yong
    Shang, Yiman
    Xu, Benling
    Guo, Jindong
    Qin, Peng
    Han, Lu
    Fu, Xiaomin
    Lin, Hongwei
    Liu, Liang
    Ren, Xiubao
    Wang, Zibing
    Gao, Quanli
    FRONTIERS IN IMMUNOLOGY, 2022, 12